Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 4/20 | 0.53 |
| ▸ | MAOA | P21397 | 1/20 | 0.49 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.45 |
| ▸ | F2 | P00734 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3979529 | 0.84 | JAK2 (0.44) | MAOBFFAR1MAPTALDH1A1CYP2D6 | |
| SCHEMBL3974986 | 0.79 | PTGER4 (0.44) | MAOBFFAR1MAPK1 | |
| SCHEMBL3975517 | 0.78 | ALDH1A1 (0.42) | MAOBMAOAALDH1A1CYP1A2CYP2C19 | |
| SCHEMBL27605303 | 0.78 | JAK2 (0.39) | MAOBFFAR1MAPTLMNA | |
| SCHEMBL3981898 | 0.77 | PTGER4 (0.42) | FFAR1MAPTALDH1A1MAPK1 | |
| SCHEMBL3977084 | 0.75 | ALDH1A1 (0.52) | FFAR1MAPTALDH1A1LMNACYP1A2 | |
| SCHEMBL3977097 | 0.74 | FNTA (0.46) | MAPTALDH1A1LMNA | |
| SCHEMBL3975215 | 0.74 | PPARG (0.53) | MAOBMAPTALDH1A1LMNA | |
| SCHEMBL3979355 | 0.74 | MAPT (0.45) | MAPTALDH1A1MAPK1LMNA | |
| SCHEMBL3973262 | 0.74 | GPR132 (0.42) | MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7514452-B2 | 2-furancarboxylic acid hydrazides and pharmaceutical compositions containing the same | DAINIPPON PHARMACEUTICAL CO., LTD (JP) | 2009-04-07 | — | — | US | disclosed |
| US-20050171196-A1 | 2-Furancarboxylic acid hydrazides and pharmaceutical compositions containing the same | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2005-08-04 | — | — | US | disclosed |
| EP-1489077-A1 | 2-FURANCARBOXYLIC ACID HYDRAZIDES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 2004-12-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171196-A1 | 2-Furancarboxylic acid hydrazides and pharmaceutical compositions containing the same | GLP1R, GCGR, GPR119 | MAOB 971/4885MAOA 1046/4885FFAR1 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.